Sensible Biotechnologies raises $47 million for mRNA platform
Sensible Biotechnologies has secured $47 million in financing, including a Series A led by Oxford Science Enterprises and up to $20 million in non-dilutive funding, to advance its naturally modified mRNA platform. The funds will support the scale-up of its VECTOR platform and clinical-grade manufacturing capabilities,